1. 2009
2. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

   Research output: Book/Report › Commissioned report

3. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

   Research output: Book/Report › Commissioned report

4. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

   Research output: Book/Report › Commissioned report

5. Published

   Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.

   Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Jan 2009.

   Research output: Contribution to conference › Paper

6. Published

   Biosimilars: Evidential standards for health technology assessment.

   Hughes, D. & Hughes, D. A., 1 Jan 2009.

   Research output: Contribution to conference › Paper

7. Published

   Biosimilars: Evidential standards for health technology assessment.

   Hughes, D. & Hughes, D. A., 1 Jan 2009.

   Research output: Contribution to conference › Paper

8. Published

   Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR?

   Hughes, D., Nichol, M., Manias, E., Hughes, D. A. & Schabert, V. F., 1 Jan 2009.

   Research output: Contribution to conference › Paper

9. Published

   Drug evaluation and pharmocoeconomics.

   Hughes, D., Krska, J., Hughes, D. A., Winfield, A. J. (Editor), Rees, J. A. (Editor) & Smith, I. (Editor), 1 Jan 2009, Pharmaceutical Practice: 4th Edition.. 2009 ed. Churchill Livingstone, p. 185-198

   Research output: Chapter in Book/Report/Conference proceeding › Chapter

10. Published

    Economic evaluation of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Jan 2009.

    Research output: Contribution to conference › Paper

11. Published

    Engaging with the MRC Methodology Hubs – NWHTMR.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

12. Published

    Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.

    Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Jan 2009.

    Research output: Contribution to conference › Paper

13. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.

    Research output: Contribution to conference › Paper

14. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.

    Research output: Contribution to conference › Paper

15. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009, p. O41.

    Research output: Contribution to conference › Paper

16. Published

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

17. 2008
18. Published

    Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens

    Hughes, D. & Hughes, D. A., 1 Dec 2008, In: British Journal of Clinical Pharmacology. 65, 6, p. 871-878

    Research output: Contribution to journal › Article › peer-review

19. Published

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Nov 2008.

    Research output: Contribution to conference › Paper

20. Published

    Methodological Issues in the literature on costs of non-compliance in chronic diseases.

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008, In: Value in Health. 11, 6, p. A571-A572

    Research output: Contribution to journal › Article › peer-review

21. Published

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008.

    Research output: Contribution to conference › Paper

22. Published

    The all wales medicines strategy group: assessments and appraisals

    Hughes, D. & Hughes, D. A., 1 Nov 2008.

    Research output: Contribution to conference › Paper

23. Published

    Medicines concordance and game theory.

    Hughes, D. & Hughes, D. A., 1 Oct 2008, In: British Journal of Clinical Pharmacology. 66, 4, p. 577

    Research output: Contribution to journal › Article › peer-review

24. Published

    Economic considerations for pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Jun 2008.

    Research output: Contribution to conference › Paper

25. Published

    Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

    Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 May 2008.

    Research output: Contribution to conference › Paper

26. Published

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.

    Research output: Contribution to conference › Paper

27. Published

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.

    Research output: Contribution to conference › Paper

28. Published

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.

    Research output: Contribution to conference › Paper

29. Published

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Apr 2008.

    Research output: Contribution to conference › Paper

30. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Mar 2008

    Research output: Non-textual form › Web publication/site

31. Published

    Statistical comments are unfounded.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Mar 2008, In: Value in Health. 11, 2, p. 346

    Research output: Contribution to journal › Article › peer-review

32. Published

    The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

    Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Mar 2008.

    Research output: Contribution to conference › Paper

33. Published

    Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conference › Paper

34. Published

    From efficacy to cost-effectiveness: Impact of patient compliance

    Hughes, D. & Hughes, D. A., 1 Feb 2008.

    Research output: Contribution to conference › Paper

35. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

36. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

37. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

38. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

39. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

40. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

41. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

42. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

43. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

44. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

45. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

46. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

47. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

48. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

49. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

50. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

51. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

52. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report